Pulmicort Nebuamp · DIN 01978918 · 0.25 mg/mL · Inh suspension
Limited Use, Reason for Use code 260, 261, 262, 263, 264 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 260, 261, 262, 263, 264 required
Write on scriptone applicable Reason for Use code, 260 or 261 or 262 or 263 or 264 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 260, 261, 262, 263, 264
Coverage limit:
For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.
Reason for Use code 260
Children aged 6 years or less;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 261
Patients who have a tracheostomy;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 262
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 263
Patients with severe mental or physical disabilities;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 264
Patients who have previously used nebulizer therapy within the last 12 month period.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: innoviCares lists Pulmicort Nebuamp (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Pulmicort Nebuamp · DIN 01978918
Manufacturer: AstraZeneca; listing date 1996-10-01
Health Canada: Marketed since 2000-01-29 · brand PULMICORT NEBUAMP 0.25 MG/ML · ATC R03BA02 BUDESONIDE · form Suspension · route Inhalation · ingredients BUDESONIDE 0.25 MG/ML · company Astrazeneca canada inc · schedule Prescription
Ministry pays: $0.2395 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01978918)
Source record
DIN 01978918: Pulmicort Nebuamp
Raw flags: sec12=Y, sec3=Y
Item: 680400077; group id 704; item number 1738; lccId 00107; manufacturer id AZC
Source form: Inh Susp; strength: 0.25mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5560; ministry $0.2395
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01978918
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13191
Interchangeable products
Taro-Budesonide · DIN 02494272 · $0.2395
Teva-Budesonide · DIN 02535416 · $0.2395
Shortage status: resolved shortage (ended January 3, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01978918
Shortage record checked October 6, 2026